Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions
Small · 2024
DOI: 10.1002/smll.202307502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, 2024. Verfasst von Judit Morla-Folch und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. Hauptthemen laut MEDLINE: Nanoparticles. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 319 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIH HHS.
Abstract (Originalsprache)
Nanomaterials have revolutionized medicine by enabling control over drugs’ pharmacokinetics, biodistribution, and biocompatibility. However, most nanotherapeutic batches are highly heterogeneous, meaning they comprise nanoparticles that vary in size, shape, charge, composition, and ligand functionalization. Similarly, individual nanotherapeutics often have heterogeneously distributed components, ligands, and charges. This review discusses nanotherapeutic heterogeneity's sources and effects on experimental readouts and therapeutic efficacy. Among other topics, it demonstrates that heterogeneity exists in nearly all nanotherapeutic types, examines how nanotherapeutic heterogeneity arises, and discusses how heterogeneity impacts nanomaterials’ in vitro and in vivo behavior. How nanotherapeutic heterogeneity skews experimental readouts and complicates their optimization and clinical translation is also shown. Lastly, strategies for limiting nanotherapeutic heterogeneity are reviewed and recommendations for developing more reproducible and effective nanotherapeutics provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
- Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
ORCID-Profile: Judit Morla-Folch, Anna Ranzenigo, Zahi Adel Fayad, Abraham Jozef Petrus Teunissen
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NIH HHS
- National Institutes of Health
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Morla-Folch, J., Ranzenigo, A., Fayad, Z. A., & Teunissen, A. J. P. (2024). Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions. Small. https://doi.org/10.1002/smll.202307502
Vancouver
Morla-Folch J, Ranzenigo A, Fayad ZA, Teunissen AJP. Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions. Small. 2024. doi:10.1002/smll.202307502
BibTeX
@article{MorlaFolch2024,
author = {Morla-Folch, Judit and Ranzenigo, Anna and Fayad, Zahi Adel and Teunissen, Abraham Jozef Petrus},
title = {Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202307502}
}
EUVIMED